Community input sought for trauma study at UCHealth Memorial Hospital Central

May 15, 2023
A photo of UCHealth Memorial Hospital Central in Colorado Springs.
UCHealth Memorial Hospital Central


UCHealth Memorial Hospital Central is seeking community input for a clinical trial to determine whether a blood clotting drug, given soon after arrival in the emergency department, can improve survival.

The virtual meetings are:

For more information, see below:

Bleeding out is the most common cause of preventable death after an injury. Researchers at UCHealth Memorial Hospital Central are asking for community input on whether they should participate in an international study to see if a blood clotting drug, given soon after arrival in the emergency department, can improve survival.

Kcentra® (or 4-factor Prothrombin Complex Concentrate) is a Food and Drug Administration (FDA)-approved drug and is currently used to reverse the effects of medications given to “thin” the blood for patients who experience bleeding and/or require surgery.

The Trauma and Prothrombin Complex Concentrate (TAP) Trial will evaluate the effectiveness of Kcentra®, in addition to all standard care, in injured patients predicted to require a large-volume blood transfusion.

“There is evidence that Kcentra® may reduce the chance of dying in injured patients who are not on blood-thinning medications,” explains Dr. Thomas Schroeppel, a trauma surgeon at Memorial Hospital Central.

“The standard treatment of injured patients who are bleeding involves the transfusion of different types of blood products, as well as the use of medications to help the blood clot better, along with surgery to stop the bleeding. But even with these treatments, up to 30% of patients suffering from a serious traumatic injury die,” said Dr. Schroeppel. “Finding a way to improve that survival rate is our highest priority here at Memorial Hospital Central.”

Patients in this study will have suffered a serious and potentially life-threatening injury, causing significant blood loss and requiring immediate lifesaving interventions. These types of injuries occur unexpectedly, and it will not be possible for most people to sign up to participate ahead of time. Most patients will be unconscious, unable to speak or hear, and too sick to consent to immediate treatment or participation in the study.

If the community feedback is positive and an independent review board (IRB) approves the study at Memorial Hospital Central, then the hospital will participate in this trial. Community members who do not want to participate can request a bracelet indicating this. If feasible, doctors will consent patients who fit the study criteria. If consent is not feasible, patients who fit the criteria will be automatically enrolled without their individual consent if they are not wearing an opt-out bracelet.

The TAP trial will be conducted in about 120 leading trauma centers in several countries and will include 8,000 patients, making it the second-largest trauma trial ever conducted. Researchers estimate the trial will begin in late-summer 2023 and last until 2026, and is funded by CSL Behring, a global biotherapeutics leader that makes Kcentra®.

“The results of this study have the potential to change the way trauma patients are treated,” said Dr. Schroeppel. “If we can determine that Kcentra® is safe and effective for trauma patients, we can transform the standard of care for bleeding trauma patients and save thousands of lives.”

The researchers are asking for feedback from the Pikes Peak region community about this study to help determine whether the community wants the hospital to participate in this study. Please consider completing a very brief anonymous survey hosted by the local study site. To complete the anonymous survey on your thoughts about this exception from informed consent study, please click here.

The researchers invite all interested in learning more about the TAP Trial at UCHealth Memorial Hospital Central to attend an online community forum. Pre-registration is not required. Dates, times and ZOOM links may be found on Memorial Hospital Central’s study website.

Questions may also be directed UCHealth Memorial Hospital’s Trauma Research program at: [email protected]

About the author

Cary Vogrin is a media relations specialist for UCHealth. She joined UCHealth in 2015, coordinating media stories and responding to media requests for UCHealth hospitals and clinics in southern Colorado.

Prior to joining UCHealth, Vogrin was a newspaper reporter and editor, having worked at The Fort Dodge Messenger in Fort Dodge, Iowa; The Contra Costa Times in Walnut Creek, California; The Rocky Mountain News in Denver, Colorado; and The Gazette in Colorado Springs, where she covered health care.